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Abstract
Background: Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic
profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety
properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation with a reference, commercially
available PEG-IFN alpha-2a in healthy male volunteers.
Methods: A randomized, crossover, double-blind study with a 3-weeks washout period, was done. A single 180
micrograms PEG-IFN alpha-2 dose was administered subcutaneously in both groups. Sixteen apparently healthy
male subjects were included. Serum PEG-IFN concentration was measured during 336 hours by an enzyme
immunoassay (EIA). Other clinical and laboratory variables were used as pharmacodynamic and safety criteria.
Results: The pharmacokinetic comparison by EIA yielded a high similitude between the formulations. In spite of a
high subject variability, the parameters’ mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL;
Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs. 64.8 h; terminal elimination rate (lambda): 0.011
vs. 0.014 h
-1; mean residence time (MRT): 135 vs. 123 h for reference and study preparations, respectively. There
were no significant differences with respect to the pharmacodynamic variables either: serum neopterin and beta-2
microglobulin levels, stimulation of 2’5’ oligoadenylate synthetase expression, and serum IFN antiviral activity. A
strong Spearman’s rank order correlation (p < 0.01) between the pharmacokinetic and pharmacodynamic
concentration-time curves was observed. Both products caused similar leukocyte counts diminution and had similar
safety profiles. The most frequent adverse reactions were leukopenia, fever, thrombocytopenia, transaminases
increase and asthenia, mostly mild.
Conclusions: Both formulations are fully comparable from the pharmacokinetic, pharmacodynamic, and safety
profiles. Efficacy trials can be carried out to confirm clinical similarity.
Trial registration: Registro Público Cubano de Ensayos Clínicos RPCEC00000039.
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Binding of interferon (IFN) alpha to polyethylene-glycol
(PEG) represented a remarkable step forward to face the
major drawbacks of the conventional IFN formulations.
The slow clearance of PEG-IFN alpha maintains viral
replication inhibitory concentrations longer time, lead-
ing to more effectiveness and fewer administrations. On
the other hand, the circulating IFN peak levels are
much lower, therefore less intense adverse reactions are
induced [1,2].
Two separate versions of PEG IFN alpha-2 have been
developed, in correspondence to the existent IFN alpha
preparations. Despite the almost identity of IFN alpha-
2a and alpha-2b molecules (only one aminoacid different
in position 23, not related to the receptor binding site),
the polyethylene glycol (PEG) used for each one is dif-
ferent, which supposes differences in their clinical use.
The product PEG IFN alpha-2a (PEGASYS®), contains a
40-kDa branched PEG, while the PEG IFN alpha-2b
(PEG-INTRON®) contains a linear 12-kDa PEG. The
molecular size of the attached PEG molecule correlates
with the protein’s in vivo half-life. Both products have
been approved for the treatment of patient with chronic
hepatitis C. Monotherapy with PEG-IFN led to 40% sus-
tained virological response. Afterwards, their combina-
tion with ribavirin was approved, rising the responders
to 61% [3]. Pegylated interferon is also indicated for the
treatment of chronic hepatitis B [4].
Recently, a new conjugate of IFN alpha-2b with 40-
kDa branched PEG was obtained in order to cope with
nationwide needs. This conjugate demonstrated appro-
priate thermal stability and less susceptibility to degra-
dation by proteases than the unmodified protein.
Additionally, a significantly longer half-life was observed
in animal models [5]. The objective of this study was to
compare its pharmacokinetic, pharmacodynamic and
safety profiles with those of a similar molecular weight,
commercially available, reference preparation. PEG IFN
alpha-2a was chosen because it was expected that the
pharmacokinetics of the experimental molecule should
be closer to it than to commercially available PEG IFN
alpha-2b which has a different pegylation. Classical IFN-
inducible biological markers (neopterin, b2-microglobu-
lin, and 2’5’ oligoadenylate synthetase) as well as the
antiviral activity in serum were used as indicators of
their pharmacodynamic action.
Methods
A randomized, crossover, double-blind study with a
three-weeks washout period was carried out at the
National Center for Toxicology, Havana, Cuba, which is
a reference unit for bioavailability and bioequivalence
studies. The trial was in compliance with the Helsinki
Declaration. The protocol was approved by the Ethics
Committee of the National Center for Toxicology, and
by the Cuban Regulatory Authority.
Subjects
Sixteen healthy, male volunteers, who gave their writ-
ten, informed consent to participate, were included.
Individuals were considered healthy if they had no his-
tory of chronic diseases, did not suffer any acute illness
in the previous 30 days, had no symptoms or signs at
the physical examination and laboratory tests, and
were negative to HIV and hepatitis B and C virus
infections markers in serum. Subjects were not
included if they had received treatment with IFN or
any other drug that could alter immune functions in
the previous 15 days, had been operated in the pre-
vious 6 months or had donated blood in the previous
3 months. They were withdrawn from the trial if they
abandoned voluntarily, had severe adverse reactions, or
if any exclusion criteria arose.
PEG IFN alpha-2 formulations
Formulation A consisted in a commercially available
preparation (PEGASYS®, Hoffmann-La Roche, Switzer-
land) presented in pre-filled syringes containing 180 μg
PEG IFN alpha-2a, 0.025 mg polysorbate 80, 4.0 mg
NaCl, 5.0 mg benzyl alcohol, 1.31 mg tri-hydrated
sodium acetate, 0.023 mg acetic acid, and water for
injection to complete 0.5 ml. Formulation B was in
vials containing 180 μg PEG IFN alpha-2b (produced
at the Center for Genetic Engineering and Biotechnol-
ogy, Havana), 0.1 mg polysorbate 80, 4.89 mg NaCl,
1.0 mg di-hydrated sodium EDTA, 12.68 mg
Na2HPO4,3 . 4 3m gN a H 2PO4.2H2O, and water for
injection to complete 1 ml.
Study design
The study was not designed to proof similarity; only to
compare the pharmacologic properties of the new
experimental molecule with an established one. After
overnight fasting, sixteen subjects received subcuta-
neously, on the upper right arm, 180 μg( d o s ec o m -
monly used for the reference preparation in clinics) of
one of the PEG-IFN preparations (A or B), in a double-
blind, randomized, crossover design with a three-week
washout period between treatments. Subjects were ran-
domized, according to a computer-generated simple
random number list, to receive one of two treatment
sequences (AB or BA). The study was double blinded.
As the presentation of the products differed, blinding
was kept by loading formulation B vials in syringes
coded with the patients’ inclusion numbers, and the
nurse that administered the products did not participate
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were hospitalized during the first 96 hours after the
injection under strict medical supervision. Blood sam-
pling and adverse reactions monitoring continued
ambulatorily until 336 hours. Antipyretic medication
was given orally at the same time as the PEG-IFN injec-
tion and every 4 hours thereafter, up to 12 hours or
more if needed, in order to mitigate the expected
IFN-dependent flu-like syndrome.
Clinical and laboratory evaluations
Blood samples for serum PEG-IFN concentration deter-
minations were collected by venipuncture before and 6,
12, 24, 36, 48, 60, 72, 84, 96, 120, 168, 216, 264, and
336 hours after injection. Pharmacodynamics was
assessed by neopterin and b2-microglobulin (b2M) con-
centrations in serum before and at 6, 12, 24, 48, 72, 96,
120, 168, and 336 hours and by the induction of 2’,5’
oligoadenylate synthetase (2’,5’ OAS) mRNA expression
before and at 6, 48, 168 and 336 hours. Serum IFN anti-
viral activity before injection and at peak blood level
was also used as pharmacodynamic evaluation. Other
hematological (hemoglobin, hematocrit, platelet, and
total and differential leukocyte counts) and biochemical
(transaminases, creatinine) determinations were taken as
safety variables, every 24 hours during the first week
and at 336 hours. Patients were regularly checked for
vital signs and symptoms during the whole study.
PEG IFN alpha-2 was quantified in serum with a high
sensitivity enzyme immunoassay (EIA) kit (Biotrak, GE
Healthcare Bio-Sciences). This EIA was previously vali-
dated to determine PEG-IFN, despite being originally
designed for non-conjugated IFN alpha-2 (result not
shown). Neopterin in serum was determined by a com-
mercial EIA kit (HENNING test, BRAHMS Diagnostica
GmbH, Berlin, Germany) as well as serum b2M (Quanti-
kine® IVD®, R&D System, Inc, Minneapolis). IFN anti-
viral activity titration in serum was done by inhibition
of Mengo virus cytopathic effect on HEp-2 cells [6].
Titers were adjusted with a laboratory reference pre-
paration that was calibrated against the international
WHO IFN alpha standard 95/566. Blood chemistry and
hematological counts were done according to usual clin-
ical laboratory procedures. For all laboratory determina-
tions, the analysts were blind with regard to the identity
of the subject.
Quantification of 2’,5’ OAS expression was performed
using a Real-Time PCR for mRNA. Briefly, 2.5 ml
human whole blood were collected and centrifuged to
pellet nucleic acids in a PAXgene Blood RNA Tube.
The pellet was washed and re-suspended, then was incu-
bated with proteinase K. Cell lysate was applied to a
PAXgene RNA spin column and purified on silica mem-
brane, the membrane was treated with DNase I, washed
and finally RNA was eluted and heat-denatured. Real-
Time PCR for purified total RNA was performed using
QuantiTect® SYBR® Green PCR (QIAGEN GmbH,
Germany), using appropriate primers and samples
according to the manufacturer’sp r o t o c o l .I nb r i e f ,1μl
of cDNA was added to 10 μl of 2x PCR master mix, 8
μl of RNase-free water, and 0.5 μlo fe a c hp r i m e r( 2 0
μM), for a total volume of 20 μl. All PCR experiments
were performed by triplicate. The ratios between target
cDNA and 18S ribosomal RNA were evaluated and
expressed as relative amount of 2’,5’ OAS mRNA
expression. The REST 2005 software (Corbett Research,
Mortlake, Australia) was used for this quantification.
Data analysis
The drug disposition data analysis was performed per
individual by a non-compartmental method with a com-
bined linear/log - linear trapezoidal rule approach. The
linear trapezoidal rule was used up to peak level and the
logarithmic trapezoidal rule thereafter. The first-order
rate constant associated with the curve terminal (log lin-
ear) portion (l) and terminal half-life (t1/2)w e r ee s t i -
mated by linear regression of the included terminal data
points. Time-to-peak values (Tmax) were determined
directly from the experimental data as the time of maxi-
mum observed level (Cmax) considering the entire
curve. Area under the serum concentration-time curve
from 0 to 336 hours (AUC336) was calculated using
the linear/log linear trapezoidal rule. Mean residence
time (MRT) was also calculated using the moments of
the drug disposition curve. Parameters that were extra-
polated to infinity, such as AUC (area under disposition
curve) and AUMC (area under first moment of the dis-
position curve) were computed based on the last pre-
dicted value from the linear regression performed to
estimate l and t1/2. Other pharmacokinetic parameters
were also calculated, such as the systemic clearance
(CL), distribution volume (Vd), and the peak to area
ratio value (CAV = Cmax/AUC). For a better characteri-
zation of the slower absorption and elimination pro-
cesses due to the pegylation, the parameters mean
absorption time (MAT) and half value duration (HVD)
were estimated. Some similar kinetic parameters were
estimated for the pharmacodynamic markers, corrected
for baseline values, neopterin and b2Mi no r d e rt o
describe the kinetic behavior of the IFN-induced immu-
nological response: AUEC (area under the effect curve),
Rmax (maximum response), T(Rmax) (time to reach
maximum response), MET (mean effect time), RAV
(average response). The WinNonlin professional soft-
ware (Version 2.1, Pharsight Inc., 1997, NC, USA) was
used for all these purposes.
Statistical analyses were done using SPSS for Windows
version 15.0, and STATISTICA for Windows version 6.1.
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groups, the Mann-Whitney’sUo rS t u d e n t ’stt e s t
(depending on the normality assumption) was applied for
continuous control variables and the chi-square or Fish-
er’s exact test for the categorical ones. Pharmacokinetic
parameters were tested for normal distribution by the
Shapiro-Wilk’s test and for variance homogeneity by the
Levene’s test. To compare formulations paired analysis
(Student’s t test or Wilcoxon’s test) depending on the
normality assumption were used. Confidence intervals
(90%) for the difference between pharmacokinetic para-
meters were calculated according to Westlake [7]. The
Wilcoxon method, proposed by Steinijans [8] was used
for the parameters that did not fulfill the normality
assumption. The 90% confidence intervals were estimated
by the non parametric method proposed by the same
authors [8]. The pharmacodynamic variables neopterin
and b2M were treated similarly. Spearman rank correla-
tion analyses between these AUEC and PEG IFN concen-
tration AUC was done. IFN antiviral activity, 2’,5’ OAS,
vital signs and clinical laboratory variables were treated
using paired analysis (Student’s t test or Wilcoxon’st e s t )
depending on the normality assumption, taking into
account Bonferrony’s adjustment for multiple compari-
sons. The calculated significance level (a) is indicated
below the corresponding Table. Adverse reactions
between formulations were compared using the McNe-
mar’s test.
Results
Sixteen healthy male volunteers were recruited. The
demographic and baseline characteristics of the sub-
jects, grouped by sequence of treatment, are shown in
Table 1. The hypothesis of homogeneity between the
groups was accepted. All the individuals complied with
the treatment and evaluations as previewed. Surpris-
ingly, one subject (No.13) presented very low PEG-IFN
levels after the administration during both periods and
did not have any pharmacodynamic effect either.
Therefore he was excluded from the pharmacokinetic
and pharmacodynamic analyses and only taken into
account for safety. He developed mild fever and mod-
erate leukopenia.
Pharmacokinetic analysis
Except for two subjects in the second period with For-
mulation B, who had 23 and 27 pg/ml, all had low basal
serum IFN concentrations (1,8 pg/ml and 2,4 pg/ml
before the first and second period, respectively). Table 2
shows the results of the PEG-IFN pharmacokinetic com-
parisons. The mean values for the parameters were very
similar between the formulations despite the subject
-dependant variability observed (see SD). A formulation
effect was not detected for any of the parameters (p >
0.05 in all cases). All the 90% confidence intervals
included the value 1. The average concentration profiles
obtained for both formulations were very similar (Figure
1). At 336 hours after the injection, serum PEG-IFN
concentrations had returned near to the initial values, so
the AUC336 obtained covered, in most of the cases,
more than 95% of the AUC extrapolated to infinite. No
residual effect from the first treatment period on the
second period IFN concentration values was found.
Pharmacodynamic analysis
Average serum neopterin increments were very similar
for both PEG IFN alpha-2 formulations, with the same
profiles (Figure 2A). The induced increments approxi-
mately tripled the basal values 48 hours after injection,
and then slowly returned to baseline. Figure 2B shows
the same high similitude between the formulations with
respect to mean serum b2-microglobulin increments,
which peaked around 60% from baseline at 72 hours for
both formulations. A pharmacokinetic-like analytical
procedure was carried out with both variables (Table 3).
No difference between the formulations was detected
for the estimated parameters, although a high intra-sub-
ject variability was again evidenced. The confidence
intervals of the test/reference ratios included 1. Both
pharmacodynamic markers significantly correlated with
Table 1 Demographic and baseline characteristics of the groups of treatment
Variables AB sequence N = 8 BA sequence N = 8 Total N = 16
Age (years) 27 ± 4 (24 - 35) 28 ± 5 (21 - 35) 27 ± 4 (21 - 35)
Weight (Kg) 70 ± 11 (60 - 92) 77 ± 12 (58 - 94) 74 ± 12 (58 - 94)
Height (cm) 175 ± 8 (164 - 185) 178 ± 8 (165 - 192) 176 ± 8 (164 - 192)
Body Mass Index 22.9 ± 2.7 (19.0 - 28.4) 24.2 ± 2.6 (20.9 - 29.3) 23.6 ± 2.6 (19.0 - 29.3)
Body surface (m
2) 1.84 ± 0.29 (1.58 - 2.42) 2.03 ± 0.32 (1.53 - 2.48) 1.94 ± 0.31 (1.53 - 2.48)
Skin color
White 6 (75%) 7 (87.5%) 13 (81.3%)
Non-white 2 (25%) 1 (12.5%) 3 (18.7%)
Data are reported as mean ± standard deviation (range) or number of patients (%).
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tions, according to the calculated AUC and AUEC. A
stronger correlation was obtained for b2-microglobulin
(Table 4). At the end of the sampling period (336
hours), concentrations of the induced markers (espe-
cially b2-microglobulin) had not fully returned to
baseline, but this did not determine a residual effect for
the second period.
Since the induction of the enzyme 2’,5’ OAS was mea-
sured through the relative amount of mRNA expression
using Real-Time PCR, an important individual variability
was observed. Therefore, parameters could not be
Table 2 Pharmacokinetic parameters calculated from the PEG-IFN concentration in serum
Parameter Formulation A N = 15 Formulation B N = 15 p 90% CI
AUC (pg.h/mL) 53623 ± 37517 44311 ± 26035 0.125 (0.66 – 1.03)
Cmax (pg/mL) 333 ± 205 271 ± 206 0.26 (0.62 – 1.06)
Tmax (h) 48 ± 24 48 ± 48 0.80 (0.78 – 1.33)
l (h
-1) 0.011 ± 0.004 0.014 ± 0.008 0.38 (0.90 – 1.52)
t1/2 (h) 72.4 ± 28.1 64.8 ± 29.6 0.45 (0.71 – 1.12)
MRT (h) 135 ± 43 123 ± 41 0.38 (0.78 – 1.06)
CAV 0.008 ± 0.003 0.008 ± 0.003 0.56 (0.93 – 1.17)
CL/F (L/h)* 7.9 ± 12.4 7.4 ± 15.6 0.16 (0.57 – 1.70)
Vd/F (L)* 720 ± 1205 841 ± 2130 0.69 (0.61 – 2.23)
MAT (h) 33.0 ± 13.2 29.1 ± 14.0 0.26 (0.77 – 1.15)
HVD (h) 126 ± 66.5 153 ± 113 0.34 (0.89 – 1.56)
Data are reported as mean ± standard deviation, except for Tmax expressed as median ± quartile range.
CI: confidence intervals of the mean Test/Reference ratio.
One volunteer (#13) was excluded from the pharmacokinetic comparison (see text).
* Parameters corrected by corporal surface.
p: Paired t test between groups, except for Tmax (Wilcoxon’s test).
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Figure 1 Average PEG-IFN concentration in serum. Data correspond to 15 healthy male subjects who received 180 μg of PEGASYS® (solid
line) and 40-kDa PEG IFN alpha-2b (dashed line). Standard deviations are not shown for the sake of simplicity of the illustration.
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Figure 2 Increments of the pharmacodynamic markers neopterin and b2M. Data correspond to 15 healthy male subjects who received 180
μg of PEGASYS® (solid line) and formulation of 40-kDa PEG IFN alpha-2b (dashed line) at time 0. (A): Average neopterin concentration in serum,
measured by EIA. (B): Average b2-microglobulin concentration in serum, measured by EIA. Standard deviations are not shown for the sake of
simplicity of the illustration.
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analysis was essentially qualitative. 2’,5’ OAS mRNA
levels two or more times with regard to their initial
values increased in 14/15 subjects with the Formulation
A and 13/15 with the Formulation B. The higher incre-
ments were obtained within the first 48 hours. No resi-
dual effect was observed.
On the other hand, PEG IFN alpha-2 exhibited a
direct antiviral activity. Baseline titers were negligible
and most of the individuals increased notably their med-
ian serum titers at Tmax by EIA similarly for both for-
mulations (Table 5). Titers correlated significantly with
the EIA measured concentration.
Safety analysis
A d v e r s ee v e n t sw e r er e c o r d e dd u r i n gt h ew h o l es t u d y .
All the subjects presented at least one event with both
formulations (Table 6). There were no differences
between formulations concerning the frequency of
adverse events, except for ardor at site of injection,
which were significantly more frequent with Formula-
tion B. The most frequent events with both formulations
were leukopenia (87.5%; due to neutropenia), fever
(56.3%), thrombocytopenia (56.3%), increase of transa-
minases (50%) and asthenia (25%). Most of them were
mild, few moderate, being well controlled. Just one sub-
ject had a severe leukopenia 24 hours after Formulation
B administration in the second period. However, this
alteration was preceded by a mild leukopenia during the
first period (Formulation A). The subject recovered nor-
mal leukocyte count spontaneously, without any other
symptom, three weeks after.
Discussion
The trial design (sample size, randomization, double
blinding, crossover, three-week washout period) com-
plied with international guidelines for pharmacokinetic
and pharmacodynamic comparisons between formula-
tions [9-11], which say that a minimum of 12 individuals
should be included in this kind of study. The facts that
more than 80% of the AUC could be covered by the
AUC336 obtained and that there was no residual effect
on the second period PEG-IFN concentrations indicate
that internal validity of the results is high. This is the
first pharmacokinetic trial where the sampling period
characterization of PEG IFN was extended beyond one
week. It is unlikely that the small amounts of baseline
endogenous IFN found in few subjects had any influence
on the results, since the PEG-IFN concentrations
attained after the administration were much higher.
The selected dose, similar to other authors, was ade-
quate, since PEG-IFN levels in serum were easily
detected and the treatment was quite well tolerated. The
crossover design is usually used in this kind of study
with other drugs. It has more statistical power to detect
differences. This study is the first comparison of differ-
ent PEG-IFN’s in a crossover, randomized fashion. The
3-weeks washout period between both treatments
seemed to be enough regarding the PEG-IFN concentra-
tion in blood. However, there was some carryover effect
Table 3 Descriptive analysis of the kinetics of serum Neopterina and serum b2-microglobulin increments.
Variable Formulation A N = 15 Formulation B N = 15 p 90% CI
Neopterin
AUEC (ng.h/mL) 500 ± 332 474 ± 257 0.75 (0.71 – 1.26)
Rmax (ng/mL) 3.6 ± 1.9 3.8 ± 2.1 0.79 (0.75 – 1.48)
T(Rmax) (h) 48 ± 24 48 ± 24 0.19 (0.61 – 1.00)
MET (h) 104 ± 36.5 108 ± 34.2 0.66 (0.88 – 1.24)
RAV 0.010 ± 0.007 0.009 ± 0.003 0.865 (0.76 – 1.20)
b2-microglobulin
AUEC (μg.h/mL) 211 ± 145 190 ± 95 0.50 (0.70 – 1.16)
Rmax (μg/mL) 1.2 ± 0.5 1.2 ± 0.5 0.99 (0.83 – 1.22)
T(Rmax) (h) 72 ± 72 72 ± 24 0.10 (0.58 – 1.00)
MET (h) 131 ± 43 161 ± 63 0.09 (1.01 – 1.50)
RAV 0.008 ± 0.005 0.006 ± 0.001 0.37 (0.71 – 1.11)
Data are reported as mean ± standard deviation, except for T(Rmax) expressed as median ± quartile range.
CI: confidence intervals of the mean Test/Reference ratio.
One volunteer (#13) was excluded from the pharmacodynamic comparison (see text).
p: Paired t test between groups, except for T(Rmax) (Wilcoxon’s test).
Table 4 Spearman rank order correlation of area under
the effect-time curves (AUEC) for neopterin and b2-
microglobulin with the PEG IFN concentration AUC
Induced protein Formulation Spearman R value p
Neopterin A 0.554 0.03
B 0.721 0.002
b2-microglobulin A 0.857 <0.001
B 0.839 <0.001
García-García et al. BMC Pharmacology 2010, 10:15
http://www.biomedcentral.com/1471-2210/10/15
Page 7 of 11for some hematological variables. Sample size was
within the range recommended for this kind of study.
The new 40 Kd PEG IFN alpha-2b fulfilled its aims:
slow absorption and elimination rates and PEG-IFN
alpha blood levels detectable until 2 weeks after a
180 μg single subcutaneous dose, very similar to the
reference product used. In a similar type of study with
the native IFN alpha-2b the mean values for t1/2 and
MRT were 5.9 h and 10.9 h, respectively [12]. After
“pegylation” these parameters were 64.8 h and 123 h,
respectively, around 11 fold higher, consistent with pre-
vious studies of 40 Kd PEG IFN alpha-2a vs. its conven-
tional IFN counterpart in healthy subjects [13,14].
Median Tmax was lower (48 h) than expected (72 h) for
both formulations, although PEG-IFN concentrations
remained close to peak levels between 36 and 84 hours
(plateau). The values found for the parameters MAT
(around 30 h) and HVD (around 150 h) corroborate the
retardation in the absorption and elimination processes.
Both formulations’ pharmacokinetics was highly simi-
lar. Differences in means did not exceed 20% for any
parameter and dispersions were also similar, although
large, which resulted in wide 90% confidence intervals
for the ratio between formulations. These differences
were due to a high intra- and inter-subject variability,
not to a formulation effect. The variability in pharmaco-
kinetic parameters in response to PEG IFN treatment is
consistent with previous studies [2,13,15,16]. In some
situations, the intra and inter-subject variability can be
equally or more important than the variation from an
innovator product to a similar. The importance of scal-
ing the established intervals based on the individual
comparison and the subject -formulation interaction has
been claimed [17].
The pharmacodynamic variables measured in this trial
are well-known IFN-induced genes, classical surrogate
markers of IFN biological actions. A key mechanism of
their antiviral activity is through induction of the
Table 5 Induction of antiviral activity in serum
Time Formulation A N = 15 Formulation B N = 15 Wilcoxon’s paired test between formulations
Baseline activity in serum 0.0 ± 1.0 (0.0; 2.5) 1.0 ± 2.0(0.0; 4.0) p = 0.187
Activity in serum at Tmax 16.0 ± 32.0(4.0; 73.0) 20.0 ± 20.0(0.0; 59.0) p = 0.513
Wilcoxon’s paired test between times p = 0.001 p = 0.001
Antiviral titers are expressed in IU/mL. Data are reported as median ± quartile range (range). One volunteer (#13) was excluded from this comparison
Table 6 Frequency of adverse events during the study
Adverse event Formulation A N = 16 Formulation B N = 16 Both formulations N = 16 p (McNemar’s test)
Any adverse event 16 (100%) 16 (100%) 16 (100%) —
Leukopenia* 14 (87.5%) 15 (93.8%) 14 (87.5%) 1.00
Fever 13 (81.3%) 11 (68.8%) 9 (56.3%) 0.69
Thrombocytopenia** 9 (56.3%) 12 (75%) 9 (56.3%) 0.25
Increase of transaminases
! 10 (62.5%) 11 (68.8%) 8 (50%) 1.00
Asthenia 8 (50%) 6 (37.5%) 4 (25%) 0.69
Headache 6 (37.5%) 7 (43.8%) 2 (12.5%) 1.00
Increase of creatinine
!! 7 (43.8%) 5 (31.3%) 0 0.77
Ardor at injection site 0 12 (75%) 0 0.0005
Erythema at injection site 5 (31.3%) 3 (18.8%) 2 (12.5%) 0.625
Hypertension 4 (25%) 2 (12.5%) 1 (6.3%) 0.625
Chills 1 (6.3%) 4 (25%) 0 0.375
Myalgias 2 (12.5%) 3 (18.8%) 1 (6.3%) 1.00
Lumbar pain 2 (12.5%) 2 (12.5%) 1 (6.3%) 1.00
Pruritus 3 (18.8%) 1 (6.3%) 1 (6.3%) 0.50
Tachycardia 2 (12.5%) 1 (6.3%) 1 (6.3%) 1.00
Somnolence 1 (6.3%) 1 (6.3%) 0 1.00
Warmth at injection site 2 (12.5%) 0 0 0.50
Hyperesthesia 2 (12.5%) 0 0 0.50
Anorexia 1 (6.3%) 0 0 1.00
Vomiting 0 1 (6.3%) 0 1.00
Arthralgias 0 1 (6.3%) 0 1.00
Data are presented as number of individuals with each adverse reaction (%).
*<5×1 0
9 cells/L;
** < 150 × 10
9 cells/L;
! > 100 UI;
!! >9 7μmol/L.
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degradation [18]. Beta2-microglobulin plays an impor-
tant role in the tumor growth control and metastases
[19]. Neopterin is an immune activation mediator of
[20]. In this study, both products behaved similarly
regarding these pharmacodynamic markers. The incre-
ments reached almost 300% for neopterin and approxi-
mately 60% for b2 M, 48-72 h after administration, as
has been reported with 40 Kd PEG-IFN alpha-2a at the
same dose and route of administration [15,16].
The integration of pharmacokinetic and pharmaco-
dynamic characterizations into drug development pro-
vides a scientific framework for its rational and
efficient application [21,22]. A significant, strong cor-
relation between plasmatic PEG-IFN alpha-2 concen-
tration AUC and the AUEC of the main
pharmacodynamic variables was evidenced for both
formulations, contrasting with other authors [16].
This correlation is an essential part of the general
comparability of pharmaceutical preparations that
contain the same or very similar active ingredient
[23]. Moreover, given the high complexity of IFN
mechanism of action, the relationship between its
blood concentration and the biological effects is not
so direct. The existing PEG IFN alpha-2a and alpha-
2b products have different pharmacokinetic properties,
but spread comparable pharmacodynamic profiles
[16]. The application of different therapeutic sche-
dules with PEG IFN alpha in hepatitis C patients
does not impact on the virological sustained response
rate [24]. In a report with 3070 adult patients with
chronic hepatitis C (genotype 1), where the classic
schedules of these two products, combined with riba-
virin, were compared, a similar virological sustained
response was obtained [25]. This situation comes
from the native IFN alpha, where also similar results
have been achieved with very different treatment
schemes in several therapeutic indications [26-28].
The IFN titration bioassay is internationally accepted
to quantify it. Its main advantage is that it directly mea-
sures the agent’s main biological activity. However, its
precision is low, which can affect the study power to
detect differences. Additionally, other cytokines could
have antiviral action as well or interfere with the assay.
Conjugation of IFN alpha-2 to PEG determines an evi-
dent loss of its in vitro activity. The antiviral activity of
the branched 40-kDa PEG-IFN is only 7% of the linear
12-kDa PEG [29]. This determination was used as
another pharmacodynamic indicator but only at baseline
and Tmax. Both formulations exhibited similar antiviral
activity levels.
One volunteer presented very low PEG-IFN concen-
trations and had no pharmacodynamic induction with
any of the products, being necessarily excluded from the
analyses, as an outlier. Interestingly, he presented
adverse events such as mild fever and moderate leuko-
penia. These events may not be mediated by the com-
mon type I IFN receptor. White blood cells count
reduction immediately after IFN injection can be related
to early cortisol release [30] and body temperature rise
is related to the interaction of IFN alpha to hypothala-
mic μ-opioid receptors [31]. This subject is being thor-
oughly studied.
Concerning safety, flu-like symptoms and hematologi-
cal count reductions were similar. All the local, systemic
and laboratory alterations recorded in this study have
been reported under the treatment of PEG IFN alpha-2
[32,33]. Except for one episode of leukopenia, the adverse
events were mild or moderate. All of them disappeared
easily. Local ardor was the only event clearly related to
the new developed product. It resolved spontaneously in
2-3 minutes and is more likely due to the excipients
rather than to the PEG IFN alpha-2b molecule.
The process to obtain a stable and effective conjuga-
tion of IFN alpha-2 and branched PEG is complex. The
details of the manufacturer are not disclosed, so it is
likely that the procedures in a compared formulation
are different. One of the most important features is the
presence of different isomers of position, which have
different biological activity since the interference
between the surface receptor and the molecule IFN is
different. This phenomenon can also affect the pharma-
cokinetic profile of PEG-IFN, since the covalent link
remains until the elimination from the body. The differ-
ence in just one aminoacid between IFN alpha-2a and
IFN alpha-2b should not determine differences in their
biological properties but some affectations after the con-
jugation with PEG could not be discarded. In this trial
both products were similar regarding their pharmacoki-
netic and pharmacodynamic profiles. In the case of
newly developed PEG IFN alpha preparations, the com-
parable pharmacokinetics and pharmacodynamics data
can be the basis for its further clinical development
were efficacy and safety information can be gathered. Its
introduction in the national health system will certainly
have a significant impact on health care.
Conclusion
The formulations have similar pharmacokinetic, phar-
macodynamic and short-term safety profiles. Efficacy
trials can be carried out to confirm clinical similarity.
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